Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2010

Open Access 01-06-2010 | Research article

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

Authors: Chad J Creighton, Xiaoyong Fu, Bryan T Hennessy, Angelo J Casa, Yiqun Zhang, Ana Maria Gonzalez-Angulo, Ana Lluch, Joe W Gray, Powell H Brown, Susan G Hilsenbeck, C Kent Osborne, Gordon B Mills, Adrian V Lee, Rachel Schiff

Published in: Breast Cancer Research | Issue 3/2010

Login to get access

Abstract

Introduction

Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype.

Methods

We defined two independent molecular signatures of the PI3K pathway: a proteomic (reverse-phase proteomic array) PI3K signature, based on protein measurement for PI3K signaling intermediates, and a PI3K transcriptional (mRNA) signature based on the set of genes either induced or repressed by PI3K inhibitors. By using these signatures, we scored each ER+ breast tumor represented in multiple independent expression-profiling datasets (four mRNA, n = 915; one protein, n = 429) for activation of the PI3K pathway. Effects of PI3K inhibitor BEZ-235 on ER expression and activity levels and cell growth were tested by quantitative real-time PCR and cell proliferation assays.

Results

Within ER+ tumors, ER levels were negatively correlated with the PI3K activation scores, both at the proteomic and transcriptional levels, in all datasets examined. PI3K signature scores were also higher in ER+ tumors and cell lines of the more aggressive luminal B molecular subtype versus those of the less aggressive luminal A subtype. Notably, BEZ-235 treatment in four different ER+ cell lines increased expression of ER and ER target genes including PR, and treatment with IGF-I (which signals via PI3K) decreased expression of ER and target genes, thus further establishing an inverse functional relation between ER and PI3K. BEZ-235 had an additional effect on tamoxifen in inhibiting the growth of a number of ER+ cell lines.

Conclusions

Our data suggest that luminal B tumors have hyperactive GFR/PI3K signaling associated with lower ER levels, which has been correlated with resistance to endocrine therapy. Targeting PI3K in these tumors might reverse loss of ER expression and signaling and restore hormonal sensitivity.
Appendix
Available only for authorised users
Literature
1.
Lin N, Winer E: Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008, 26: 798-805. 10.1200/JCO.2007.15.0946.CrossRefPubMed
2.
Osborne C: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998, 51: 227-238. 10.1023/A:1006132427948.CrossRefPubMed
3.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005, 23: 7721-7735. 10.1200/JCO.2005.09.004.CrossRefPubMed
4.
Conneely O, Jericevic B, Lydon J: Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003, 8: 205-214. 10.1023/A:1025952924864.CrossRefPubMed
5.
Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003, 21: 1973-1979. 10.1200/JCO.2003.09.099.CrossRefPubMed
6.
Bedard P, Freedman O, Howell A, Clemons M: Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?. Breast Cancer Res Treat. 2008, 108: 307-317. 10.1007/s10549-007-9606-8.CrossRefPubMed
7.
Arpino G, Wiechmann L, Osborne C, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233. 10.1210/er.2006-0045.CrossRefPubMedPubMedCentral
8.
Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets. 2008, 8: 27-36. 10.2174/156800908783497140.CrossRefPubMed
9.
Samuels Y, Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006, 18: 77-82. 10.1097/01.cco.0000198021.99347.b9.CrossRefPubMed
10.
Chen Y, Law P, Loh H: Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents. 2005, 5: 575-589. 10.2174/156801105774574649.CrossRefPubMed
11.
Hennessy B, Smith D, Ram P, Lu Y, Mills G: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4: 988-1004. 10.1038/nrd1902.CrossRefPubMed
12.
Dillon R, White D, Muller W: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 2007, 26: 1338-1345. 10.1038/sj.onc.1210202.CrossRefPubMed
13.
Creighton CJ: A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007, 26: 4648-4655. 10.1038/sj.onc.1210245.CrossRefPubMed
14.
Kirkegaard T, Witton C, McGlynn L, Tovey S, Dunne B, Lyon A, Bartlett J: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005, 207: 139-146. 10.1002/path.1829.CrossRefPubMed
15.
Shin I, Arteaga C: Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells. IUBMB Life. 2006, 58: 664-669. 10.1080/15216540601001681.CrossRefPubMed
16.
Stål O, Pérez-Tenorio G, Akerberg L, Olsson B, Nordenskjöld B, Skoog L, Rutqvist L: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003, 5: R37-44. 10.1186/bcr569.CrossRefPubMedPubMedCentral
17.
Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y: The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer. 2006, 42: 629-635. 10.1016/j.ejca.2005.11.025.CrossRefPubMed
18.
Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006, 13: 137-144. 10.2325/jbcs.13.137.CrossRefPubMed
19.
Vestey S, Sen C, Calder C, Perks C, Pignatelli M, Winters Z: Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer. 2005, 41: 1017-1025. 10.1016/j.ejca.2005.02.011.CrossRefPubMed
20.
Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao M, Mak T, Fyles A, Liu F: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer. 2003, 104: 195-203. 10.1002/ijc.10909.CrossRefPubMed
21.
Perren A, Weng L, Boag A, Ziebold U, Thakore K, Dahia P, Komminoth P, Lees J, Mulligan L, Mutter G, Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999, 155: 1253-1260.CrossRefPubMedPubMedCentral
22.
Garcia J, Silva J, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, España P, Bonilla F: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat. 1999, 57: 237-243. 10.1023/A:1006273516976.CrossRefPubMed
23.
Generali D, Fox S, Brizzi M, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris A, Berruti A: Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res. 2008, 14: 2673-2680. 10.1158/1078-0432.CCR-07-1046.CrossRefPubMed
24.
Stemke-Hale K, Gonzalez-Angulo A, Lluch A, Neve R, Kuo W, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans W, Pusztai L, Nolden L, Horlings H, Berns K, Hung M, van de Vijver M, Valero V, Gray J, Bernards R, Mills G, Hennessy B: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68: 6084-6091. 10.1158/0008-5472.CAN-07-6854.CrossRefPubMedPubMedCentral
25.
Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills G, Kornblau S: Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006, 5: 2512-2521. 10.1158/1535-7163.MCT-06-0334.CrossRefPubMed
26.
Hennessy B, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey M, Ravoori M, Gonzalez-Angulo A, Birch R, Henderson I, Kundra V, Mills G: Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007, 13: 7421-7431. 10.1158/1078-0432.CCR-07-0760.CrossRefPubMed
27.
28.
29.
Creighton C, Osborne C, van de Vijver M, Foekens J, Klijn J, Horlings H, Nuyten D, Wang Y, Zhang Y, Chamness G, Hilsenbeck S, Lee AV, Schiff R: Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009, 114: 287-299. 10.1007/s10549-008-0017-2.CrossRefPubMed
30.
31.
Saldanha AJ: Java Treeview: extensible visualization of microarray data. Bioinformatics. 2004, 20: 3246-3248. 10.1093/bioinformatics/bth349.CrossRefPubMed
32.
Gibbons D, Lin W, Creighton C, Zheng S, Berel D, Yang Y, Raso M, Liu D, Wistuba I, Lozano G, Kurie J: Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS ONE. 2009, 4: e5401-10.1371/journal.pone.0005401.CrossRefPubMedPubMedCentral
33.
Creighton C, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck S, Osborne C, Lee A: Insulin-like growth factor I (IGF-I) activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008, 26: 4078-4085. 10.1200/JCO.2007.13.4429.CrossRefPubMedPubMedCentral
34.
Creighton C, Li X, Landis M, Dixon J, Neumeister V, Sjolund A, Rimm D, Wong H, Rodriguez A, Herschkowitz J, Fan C, Zhang X, He X, Pavlick A, Gutierrez M, Renshaw L, Larionov A, Faratian D, Hilsenbeck S, Perou C, Lewis M, Rosen J, Chang J: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009, 106: 13820-13825. 10.1073/pnas.0905718106.CrossRefPubMedPubMedCentral
35.
Hoadley K, Weigman V, Fan C, Sawyer L, He X, Troester M, Sartor C, Rieger-House T, Bernard P, Carey L, Perou C: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007, 8: 258-10.1186/1471-2164-8-258.CrossRefPubMedPubMedCentral
36.
Livak K, Schmittgen T: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
37.
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR: The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006, 313: 1929-1935. 10.1126/science.1132939.CrossRefPubMed
38.
Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M, Koujak S, Ferrando A, Malmström P, Memeo L, Isola J, Bendahl P, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 2007, 104: 7564-7569. 10.1073/pnas.0702507104.CrossRefPubMedPubMedCentral
39.
Majumder P, Febbo P, Bikoff R, Berger R, Xue Q, McMahon L, Manola J, Brugarolas J, McDonnell T, Golub T, Loda M, Lane H, Sellers W: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004, 10: 594-601. 10.1038/nm1052.CrossRefPubMed
40.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
41.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JGM, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007, 25: 1239-1246. 10.1200/JCO.2006.07.1522.CrossRefPubMed
42.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed
43.
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Klijn J, Foekens J, Cardoso F, Piccart M, Buyse M, Sotiriou C, TRANSBIG_Consortium: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007, 13: 3207-3214. 10.1158/1078-0432.CCR-06-2765.CrossRefPubMed
44.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
45.
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo W-L, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral
46.
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003, 17: 575-588. 10.1210/me.2002-0318.CrossRefPubMed
47.
Osborne C, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005, 23: 1616-1622. 10.1200/JCO.2005.10.036.CrossRefPubMed
48.
Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D: Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res. 2007, 13: 7029-7036. 10.1158/1078-0432.CCR-07-0587.CrossRefPubMed
49.
Brachmann S, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira S: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA. 2009, 106: 22299-22304. 10.1073/pnas.0905152106.CrossRefPubMedPubMedCentral
50.
Baehner F, Habel L, Quesenberry C, Capra A, Tang G, Paik S, Wolmark N, Watson D, Shak S: Quantitative RT-PCR analysis of ER and PR by Oncotype DX™ indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. Breast Can Res Treat. 2006, 100: S21-abstract
51.
Lopez-Tarruella S, Schiff R: The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007, 13: 6921-6925. 10.1158/1078-0432.CCR-07-1399.CrossRefPubMed
52.
Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor {alpha}-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor {alpha}-negative human breast tumors. Cancer Res. 2006, 66: 3903-3911. 10.1158/0008-5472.CAN-05-4363.CrossRefPubMed
53.
Guo S, Sonenshein G: Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol. 2004, 24: 8681-8690. 10.1128/MCB.24.19.8681-8690.2004.CrossRefPubMedPubMedCentral
54.
Massarweh S, Osborne C, Creighton C, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68: 826-833. 10.1158/0008-5472.CAN-07-2707.CrossRefPubMed
55.
Dhasarathy A, Kajita M, Wade P: The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol. 2007, 21: 2907-2918. 10.1210/me.2007-0293.CrossRefPubMedPubMedCentral
56.
Kim H, Litzenburger B, Cui X, Delgado D, Grabiner B, Lin X, Lewis M, Gottardis M, Wong T, Attar R, Carboni J, Lee A: Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 2007, 27: 3165-3175. 10.1128/MCB.01315-06.CrossRefPubMedPubMedCentral
57.
Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush J, Stijleman I, Palazzo J, Marron J, Nobel A, Mardis E, Nielsen T, Ellis M, Perou C, Bernard P: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370.CrossRefPubMedPubMedCentral
58.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, D W, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
Metadata
Title
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
Authors
Chad J Creighton
Xiaoyong Fu
Bryan T Hennessy
Angelo J Casa
Yiqun Zhang
Ana Maria Gonzalez-Angulo
Ana Lluch
Joe W Gray
Powell H Brown
Susan G Hilsenbeck
C Kent Osborne
Gordon B Mills
Adrian V Lee
Rachel Schiff
Publication date
01-06-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2594

Other articles of this Issue 3/2010

Breast Cancer Research 3/2010 Go to the issue

Editorial

At last, a predictive and prognostic marker for radiotherapy?

Editorial

What do we learn from HER2-positive breast cancer genomic profiles?

Research article

Incorporating tumour pathology information into breast cancer risk prediction algorithms

Review

Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression

Editorial

Just when you thought it was safe to go into the membrane: the growing complexities of extra-nuclear progesterone signaling

Review

The contribution of dynamic stromal remodeling during mammary development to breast carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits